More articles from Volume 46, Issue 1, 2017
Ultraviolet A irradiation and photoaging of the mouse skin
Specificity and sensitivity of preoperative total serum prostate specific antigen in diagnosis most common histopathological change of prostate
Epidemiological characteristic of salmonellosis in Serbian areas of Kosovo and Metohija
The frequency and characteristics of regional metastases and their impact on the survival of patients with T1 and T2 laryngeal cancer
The impact of stress on occupational burnout among miners
Specificity and sensitivity of preoperative total serum prostate specific antigen in diagnosis most common histopathological change of prostate
,
Milica Mijovic
,
Danica Vukicevic
,
Branislav Djerkovic
,
Sladjana Savic
,
Leonida Vitkovic
V. Nedeljkovic
Abstract
Determination of preoperative prostate-specific antigen (PSA) value is primary procedure in diagnosis of different pathological prostate changes (prostate cancer-PC, prostatic intraepithelial neoplasia-PIN and benign prostatic hyperplasia-BPH), followed by digital rectal examination and prostate biopsy as gold standard. Disadvantage of high sensitivity and low specificity of PSA testing in diagnosis of PC is a problem in clinical practice. Aim was to determine the diagnostic performance of PSA in diagnosis of PC, PIN and BPH. The study included 100 patients divided into three groups: 70 with PC, 20 with a PIN and 10 with BPH. Patients with PIN and BPH were control group. Preoperative PSA values were determined by Tandem-R, The patients were divided into subgroups by baseline PSA level as follows: 4-10, 11-20, 21-30, 31-40 and> 40. The definitive histopathological diagnosis was made on routine hematoxylineosin slides. The area under the receiver operating characteristic curve (ROC), sensitivity-SE and specificity-SP of each PSA level were evaluated for PC. Preoperative serum PSA levels in patients with PC (median-35.82 ng/ml, min-6 ng/ml, max-960.40 ng/ml) were significantly higher than with PIN (median-9.15 ng/ml, min-3.16 ng/ml, max-27.61 ng/ml) and BPH (median-8.68 ng/ml, min0.80 ng/ml, max-31.20 ng/ml). The best diagnostic characteristics of the PSA are on limit value 10 ng/ml (AUC=0.781, SE=92.9%; SP=63.3%; p<0,0001). PSA is of great help in diagnosis of advanced and initial form of PC. The chance of PC diagnosis was greater than that for other pathological changes when PSA level was higher than 10 ng/ml.
Keywords
References
1.
Abbou C, Lobel B. Prostate specific antigen in the management of prostate cancer. 1993;12.
2.
Alexander E, Qian J, Wollan P. Prostatic intraepithelial neoplasia does not appear to raise serum prostate-specific antigen concentration. Urology. 1996;693–8.
3.
Amling C, Blute M, Lerner S, Bergstralh E, Bostwick D, Zincke H. Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc. 1998;(5):401–6.
4.
Anderson J, Strickland D, Corbin D, Byrnes J, Zweiback E. Age-specific reference ranges for serum prostate-specific antigen. Urology. 1995;54–7.
5.
Augustin H, Hammerer P, Graefen M, Palisaar J, Daghofer F, Huland H, et al. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol. 2003;(11):662–8.
6.
Borley N, Feneley M. Prostate cancer: diagnosis and staging. Asian J Androl. 2009;(1):74–80.
7.
Bouchardy C, Mirra A, Khlat M, Parkin D, De Souza J, Gotlieb S. Ethnicity and cancer risk in SaoPaulo. Brazil Cancer Epidemiol Biomarkers Prev. 1991;21–7.
8.
Brawley O. Prostate carcinoma incidence and patient mortality: the effects of screening and early detection. Cancer. 1997;1857–63.
9.
Chb B. Advances in research, diagnosis and treatman of cancer of the prostate. The Prostate. 1995;50–60.
10.
Burden H, Holmes C, Persad R, Whittington K. Prostasomes-their effects on human male reproduction and fertility. Hum Reprod Update. 2006;(3):283–92.
11.
Cancer Registry of Central Serbia, Institute of Public Health of the Republic of Serbia. 1999;
12.
Catalona W, Smith D, Wolfert R. Evaluation of persentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;1214–20.
13.
Catalona W; G, Murphy L, Denis C, Chatelain K, Griffiths S, Khoury. Clinical utility of measurements of free and total PSA: a review. First International Consultation on Prostate Cancer. 1997;104–11.
14.
Cerovi S. Parametri agresivnosti karcinoma prostate. 2009;8–22.
15.
Chan L, Stamey T. Calculating prostate cancer volume preoperatively: the D’Amico equation and some other observations. J Urol. 1998;(6):1998–2003.
16.
Collins G, Lee R, Mckelvie G, Rogers A, Hehir M. Relationship between prostate specific antigen, prostate volume and age in the benign prostate. Br J Urol. 1993;445–50.
17.
Cook P, Doll R, Fellingham S. A mathematical model for the age distribution of cancer in man. Int J Cancer. 1969;93–112.
18.
Corcoran N, Casey R, Hong M, Pedersen J, Connolly S, Peters J, et al. Goldenberg SL: The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume. BJU Int. 2012;(1):36–42.
19.
Dalkin B, Ahmann F, Kopp J. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostatic carcinoma. J Urol. 1993;1837–9.
20.
Bostwick D, Qian J. High -grade prostatic intraepithelial neoplasia. Modern Pathology. 2004;360–79.
21.
Deantoni E, Crawford E, Oesterling J, Ross C, Berger E, Mcleod D, et al. Age-and race-specific reference ranges for prostate-specific antigen from a large community-based study. Urology. 1996;234–9.
22.
Epstein J, Carmichael M, Partin A, Walsh P. Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications. J Urol. 1994;1587–92.
23.
Epstein J, Walsh P, Carter H. Dedifferentiation of prostate cancer grade with time in men followed expectantly for stage T1c disease. J Urol. 2001;1688–91.
24.
Gonzalez C, Roehl K, Antenor J, Blunt L, Han M, Catalona W. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy. Urology. 2004;(4):723–8.
25.
Greene D, Wheeler T, Egawa S, Weaver R, Scardino P. Relationship between clinical stage and histological zone of origin in early prostate cancer: morphometric analysis. Br J Urol. 1991;499–509.
26.
Originalni Radovi.
27.
Grossfeld G, Latini D, Lubeck D, Mehta S, Carroll P. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol. 2003;(1):157–63.
28.
Haukaas S, Halvorsen O, Daehlin L, Hostmark J, Akslen L. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer? BJU Int. 2006;(1):51–5.
29.
Horiguchi A, Nakashima J, Horiguchi Y, Nakagawa K, Oya M, Ohigashi T, et al. Prediction of extraprostatic cancer by prostate specific antigen density, endorectal MRI, and biopsy Gleason score in clinically localized prostate cancer. Prostate. 2003;(1):23–9.
30.
Huddart R, Rajan B, Law M, Meyer L, Dearnaley D. Spinal cord compression in prostate cancer: treatment outcome and prognostic factors. Radiother Oncol. 1997;229–36.
31.
Jemal A, Center M, Desantis C, Ward E. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;(8):1893–907.
32.
Rosai J, M. Ackerman’s Surgical Pathology, eight edition. 1996;1221–56.
33.
Jung K, Brux B, Lein M, Rudolph B, Kristiansen G, Hauptmann S, et al. Molecular forms of prostate specific antigen in malignant and benign prostatis tissue: biochemical and diagnostic implications. Clin Chem. 2000;(1):47–54.
34.
Jureti A, Maruši A, Ježek D, Šari N, Baši -Koreti M, Bišof V, et al. embriologija i fiziologija prostate. 2010;1–20.
35.
Katz A, Katz A. The top 13: what family physicians should know about prostate cancer. Can Fam Physician. 2008;(2):198–203.
36.
Kilic S, Kukul E, Danisman A. Ratio of free to total prostate-specific antigen in patients with prostatic intraepithelial neoplasia. Eur Urol. 1998;176–80.
37.
Klein E, Platz E, Thompson I. Epidemiology, etiology and prevention of prostate cancer. 2007;2854–73.
38.
Kouriefs C, Sahoyl M, Grange P, Muir G. Prostate specific antigen through the years. Arch Ital Urol Androl. 2009;(4):195–8.
39.
Li R, Guo Y, Han B, Yan X, Utleg A, Li W, et al. Proteomics cataloging analysis of human expressed prostatic secretions reveals rich source of biomarker candidates. Proteomics Clin Appl. 2008;(4):543–55.
40.
Lilja H. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin. Urol Clin North Am. 1993;681–6.
41.
Lilja H, Christensson A, Dahlen U, Matikainen M, Nilsson O, Pettersson K, et al. Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. Clin Chem. 1991;1618–25.
42.
Lojanapiwat B, Anutrakulchai W, Chongruksut W, Udomphot C. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice. Prostate Int. 2014;(3):133–9.
43.
Mai K, Isotalo P, Green J, Perkins D, Morash C, Collins J. Incidental prostatic adenocarcinomas and putative premalignant lesions in TURP specimens collected before and after the introduction of prostrate-specific antigen screening. Arch Pathol Lab Med. 2000;1454–6.
44.
Mcneal J, Price H, Redwine E, Freiha F, Stamey T. Stage A versus stage B adenocarcinoma of the prostate: morphological comparison and biological significance. J Urol. 1988;61–5.
45.
Mcneal J, Redwine E, Freiha F, Stamey T. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol. 1988;897–906.
46.
Menard J, Durlach A, Barbe C, Joseph K, Lorenzato M, Azemar M, et al. Endothelin-1: a predictor of extracapsular extension in lclinically localized prostate cancer? BJU Int. 2011;(2).
47.
Nikoli J, Mi. Tumori urogenitalnih organa. 2005;3–140.
48.
Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA. 1993;860–4.
49.
Oh J, Hong S, Lee J, Lee B, Lee S, Kwon O, et al. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int. 2012;(11).
50.
Ou Y, Chen J, Yang C, Cheng C, Ho H, Kao Y, et al. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol. 2002;(5):172–6.
51.
Partin A, Kattan M, Subong E. Combination of prostate-specific antigen, clinical stage and Gleason score to predict pathologocal stage of localisated prostate cancer. A multi-institutional update. JAMA. 1997;1445–51.
52.
Partin A, Criley S, Subong E, Zincke H, Walsh P, Oesterling J. Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis. J Urol. 1996;1336–9.
53.
Pettaway C, Troncoso P, Ramirez E, Johnston D, Steelhammer L, Babaian R. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol. 1998;(2):437–42.
54.
Ramos C, Carvahal G, Mager D, Haberer B, Catalona W. The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels. J Urol. 1999;1587–90.
55.
Reissigl A, Klocker H, Pointner J, Fink K, Horninger W, Ennemoser O, et al. Usefulness of the ratio free/total prostate-specific antigen in addition to total PSA levels in prostate cancer screening. Urology. 1996;(6A):62–6.
56.
Relji A. Klini ka slika i dijagnostika raka prostate In: Šamija M ed. Rak prostate -najvarijabilniji zlo udni tumor. 2010;69–74.
57.
Richardson T, Oesterling J. Age-specific reference ranges for serum prostate-specific antigen. Urol Clin North Am. 1997;339–51.
58.
Robel P. Prostate-specific antigen: present and future. 1994;46–56.
59.
Ronnett B, Carmichael M, Carter H. Does high grade prostatic intraepithelial neoplasia result in elevated serum prostate specific antigen levels? J Urol. 1993;386–9.
60.
Francisco S, Regan I, Olumi M, Dewolf A, W. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen. J Urol. 2004;(4):1492–9.
61.
Rjr S, Mutchnik D, Laskowski T. Schmalhorst WR: Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol. 1969;602–7.
62.
Sebo T, Bock B, Cheville J, Lohse C, Wollan P, Zincke H. The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol. 2000;(1):174–8.
63.
Smilji S, Radovi D, Nestorovi V, Milanovi Z, Biševac B. Endotelini kao medijatori u modulaciji sr anih performansi. Praxis medica. 2014;79–84.
64.
Stattin P, Bergh A, Karlberg L, Tavelin B, Damber J. Long-term outcome of conservative therapy in men presenting with voiding symptoms and prostate cancer. Eur Urol. 1997;404–9.
65.
Steinberg G, Carter B, Beaty T, Childs B, Walsh P. Family history and the risk of prostate cancer. Prostate. 1990;337–47.
66.
Stenman U, Leinonen J, Alfthan H, Rannikko S, Tuhkanen K, Alfthan O. A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res. 1991;222–6.
67.
Thomas J, Gupta M, Grasso Y, Reddy C, Heston W, Zippe C, et al. Preoperative combined nested reverse transcriptase polymerase chain reaction for prostate-specific antigen and prostate-specific membrane antigen does not correlate with pathologic stage or biochemical failure in patients with localized prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2002;(15):3213–8.
68.
Tosoian J, Loeb S. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. ScientificWorldJournal. 2010;1919–31.
69.
Vukoti V. Dijagnosti kih proces premalignih lezija i karcinoma prostate. 2009;103–23.
70.
Wang T, Hill T, Norton K, Sokoloff R. Specific immunoassay for free PSA and it s clinical relevance. J Urol. 1995;
71.
Wiley E, Davidson P, Mcintire D, Sagalowsky A. Risk of concurrent prostate cancer in cystoprostatectomy specimens is related to volume of high-grade prostatic intraepithelial neoplasia. Urology. 1997;692–6.
72.
Zagars G, Pollack A, Eschenbach V. AC: Prostate cancer and radiation therapy--the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys. 1995;(1):23–35.
73.
Zhang H, Wang H, Xu N, Li S, Ji G, Li X, et al. Mass screening of 12,027 elderly men for prostate carcinoma by measuring serum prostate specific antigen. Chin Med J (Engl). 2004;(1):67–70.
Citation
Copyright
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Article metrics
Google scholar:
See link
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
